(Albany, United States) As per DelveInsight’s assessment, globally, the Chronic Kidney Disease pipeline constitutes 76+ key companies continuously working towards developing 80+ Chronic Kidney Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Chronic Kidney Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Chronic Kidney Disease clinical trials studies, Chronic Kidney Disease NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Chronic Kidney Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight
Key Takeaways from the Chronic Kidney Disease Pipeline Report
- DelveInsight’s Chronic Kidney Disease Pipeline analysis depicts a robust space with 76+ active players working to develop 80+ pipeline treatment therapies.
- The leading Chronic Kidney Disease Companies are working in the market include Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies Inc, MISSION Therapeutics, AceLink Therapeutics, and others
- Promising Chronic Kidney Disease Pipeline Therapies in the various stages of development include roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, rHuEPO, AST-120, and others
- On Sept 2022, Astellas Pharma Inc has announced drug named roxadustat in the market by the phase 3. The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).
- On October 2022, AstraZeneca has announced drug named AZD5718 and Dapagliflozin 10 mg in the market by the phase 2. The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
Chronic Kidney Disease Overview
Chronic kidney disease (CKD) means the kidneys are damaged and can’t filter blood the way they should. Abnormalities of kidney structure or function, present for > 3 months, with implications for health are considered to be CKD.
To explore more information on the latest breakthroughs in the Chronic Kidney Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight
Chronic Kidney Disease Emerging Drugs Profile
- KBP-5074: KBP Biosciences
- Ziltivekimab: Novo Nordisk
- US-APR2020: Kibow Pharma
- DM199: DiaMedica Therapeutics
- AL-01211: AceLink Therapeutics
Chronic Kidney Disease Pipeline Therapeutics Assessment
There are approx. 76+ Chronic Kidney Disease companies which are developing the therapies for Chronic Kidney Disease. The Chronic Kidney Disease companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.
Request a sample and discover the recent advances in Chronic Kidney Disease Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight
Chronic Kidney Disease Drugs and Companies
- KERENDIA (finerenone): Bayer HealthCare Pharmaceuticals Inc
- FARXIGA (dapagliflozin): AstraZeneca
- INVOKANA (canagliflozin): Janssen Research & Development, LLC
- JYNARQUE (tolvaptan): Otsuka Pharmaceutical
- Renal Autologous Cell Therapy (REACT): ProKidney
- Bardoxolone methyl: Reata Pharmaceuticals, Inc.
Chronic Kidney Disease Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Chronic Kidney Disease Therapeutics Market include-
Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies Inc, MISSION Therapeutics, AceLink Therapeutics, and others.
Dive deep into rich insights for drugs for Chronic Kidney Disease Pipeline, click here for Chronic Kidney Disease Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight
Scope of the Chronic Kidney Disease Pipeline Report
- Coverage- Global
- Chronic Kidney Disease Companies- Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies Inc, MISSION Therapeutics, AceLink Therapeutics, and others.
- Chronic Kidney Disease Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, rHuEPO, AST-120, and others.
- Chronic Kidney Disease Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Chronic Kidney Disease Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Chronic Kidney Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chronic Kidney Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- KBP-5074: KBP Biosciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- DM199: DiaMedica Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AL-01211: AceLink Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- SCO-116: Scohia Pharma
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Kidney Disease Key Companies
- Chronic Kidney Disease Key Products
- Chronic Kidney Disease- Unmet Needs
- Chronic Kidney Disease- Market Drivers and Barriers
- Chronic Kidney Disease- Future Perspectives and Conclusion
- Chronic Kidney Disease Analyst Views
- Chronic Kidney Disease Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/out-licensing-opportunity